WND deepens industrial ties with South Korea, Australia

A WND delegation holds an exchange meeting with Australian representatives. [Photo/WeChat account: xinwu_wx]

A delegation from Wuxi National Hi-Tech District, also known as WND, recently visited South Korea and Australia to explore investment opportunities and strengthen cooperation in advanced industries and innovation.

During the visit, the delegation met with 11 leading companies, institutions and universities, including South Korea's SK Hynix and LG Chem, as well as the University of New South Wales Sydney and GMP Pharmaceuticals in Australia. It also held two roundtable meetings focused on semiconductors, new energy, new materials, food and health, and high-end equipment.

During a number of face-to-face discussions, the delegation introduced the district's industrial development plans, business advantages and latest policies supporting foreign investment. The group also heard about companies' plans for business expansion, R&D and market development, with a focus on identifying opportunities for collaboration and accelerating projects.

At the roundtable meeting in South Korea, cooperation agreements were signed with partners including Miribit and Guanlan Business School.

South Korean investment has been an important part of the district's industrial development for decades. Since the first South Korea-invested company established operations there in 1995, more than 200 companies from the neighboring nation have set up operations in the district, with combined investment exceeding $25 billion. Their businesses span advanced sectors including semiconductors, new energy, automotive components and biomedicine.

Cooperation with Australia is also advancing. WND-based Boton Technology signed a global framework agreement with BHP, expanding their partnership beyond product supply to joint technology development, green collaboration and integrated global services.

Meanwhile, Tigermed has established a coordinated model linking its Australian team with its Wuxi operations platform to help clinical research and development projects move forward more efficiently.